Related Experiment Video
Updated: Jun 5, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
Low-dose and high-dose methotrexate are two different drugs in practical terms
Anand N Malaviya1, Amit Sharma, Divya Agarwal
1Department of Rheumatology, ISIC Superspeciality Hospital, Vasant Kunj, New Delhi, India. anand_malaviya@yahoo.com
Low-dose methotrexate (LD-MTX) and high-dose methotrexate (HD-MTX) have distinct therapeutic actions and side effect profiles. Understanding these differences is crucial for appropriate clinical use and managing patient expectations.
Area of Science:
- Pharmacology
- Rheumatology
- Oncology
Background:
- Methotrexate (MTX) was initially developed as an anti-cancer agent.
- Its application expanded to immunoinflammatory diseases, particularly in rheumatology.
- Dosing differs significantly between oncological (high-dose) and rheumatological (low-dose) applications.
Purpose of the Study:
- To differentiate the therapeutic actions, indications, and adverse effects of low-dose MTX (LD-MTX) and high-dose MTX (HD-MTX).
- To clarify the distinct mechanisms of action for LD-MTX and HD-MTX.
- To address and alleviate unfounded fears regarding LD-MTX side effects by distinguishing them from HD-MTX toxicity.
Main Methods:
- Comparative analysis of extensive studies on MTX in oncology and rheumatology.
- Review of clinical data and pharmacological research differentiating LD-MTX and HD-MTX.
- Literature synthesis focusing on therapeutic outcomes and adverse event profiles.
Main Results:
- LD-MTX and HD-MTX exhibit markedly different therapeutic actions, clinical indications, and adverse effect profiles.
- The mechanisms of action for LD-MTX and HD-MTX are distinct.
- The safety and efficacy profiles are not interchangeable between the two dosing regimens.
Conclusions:
- Differentiating between LD-MTX and HD-MTX is essential for correct clinical application.
- Recognizing the distinct properties of LD-MTX can reduce patient anxiety about potential side effects.
- Accurate understanding supports appropriate treatment strategies in rheumatology and oncology.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
08:38Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Bioequivalence of Drugs: Drugs with Multiple Indications
Phase II Reactions: Methylation Reactions
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Drug Toxicity: Dose-Dependent Reactions